drugset
drugset / Trial / NCT07222956

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

NCT07222956 ↗

Phase 2 Not yet recruiting 20 enrolled Moein Amin Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS will be recruited.

Timeline

Start
2026-06-30
Primary completion
2030-10-30
Completion
2030-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Remibrutinib Small molecule 100 mg —

Indications

primary progressive multiple sclerosis relapsing-remitting multiple sclerosis secondary progressive multiple sclerosis